Luma Meds Review
Appears to have shut downLuma Meds is closed and is not taking new patients. Its lowest price, $140 a month, was paid up front.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Luma Meds is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.
Last published price before it closed: $140/mo. No longer offered.
See our top-rated GLP-1 providers →Luma Meds sold compounded semaglutide and tirzepatide by telehealth. Its site is offline. In October 2026 every page of its site, including the home page, returned “Page not found”, in two checks an hour apart.
Vetted alternatives to Luma Meds
Editorial score · methodology
Collective
Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top
Editorial score · methodology
Found
Best for: people who want clinician visits billed to commercial insurance, with compounded medication in the plan price
Editorial score · methodology
Luma Meds at a glance
- Status
- Closed: not taking new patients
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Last published price
- $140/mo (Amortized per-month rate on 3-month plan.)
- What it included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letters found
How Luma Meds scores
Luma Meds has closed. These scores describe what it published when we last checked it, before it stopped taking patients.
Six columns, each one computed from something Luma Meds published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.
Value25%
4.2/10$299/month is 11% above the $269 median for compounded tirzepatide across the sellers we compare. A cheaper plan paid several months up front is also listed.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10A price is shown before the questionnaire starts.
Trust & Safety15%
6.5/10No pharmacy is named for its prescriptions. It shows a price before asking for health information.
Accessibility10%
5.0/10No state list is available to check, so this is held at the midpoint rather than scored on reach.
Support10%
7.0/10The price covers the medication, clinician visits and shipping.
A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →
What we checked on Luma Meds
Last checked August 2026- Checked the listed price across 4 dose or plan tiers
- Checked what the monthly price covers, and what it leaves out
- Checked FDA warning letters for Luma Meds
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.
Cancelling Luma Meds
Taken from the terms Luma Meds publishes. Terms change, so check the current policy before you subscribe.
- Minimum commitment
- None
- Refund policy
- Not published by the seller
Medications Luma Meds listed
Luma Meds listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.
Prices it published before closing
Prices re-verified
Standard monthly rate; $199 first month.
Amortized per-month rate on 3-month plan.
Standard monthly rate; $249 first month.
Amortized per-month rate on 3-month plan.
In its favor
- Showed its price before the medical questionnaire, so you could compare it without handing over health information
- The monthly price included the medication, clinician visits and shipping
- We found no FDA warning letters issued to Luma Meds
Against it
- Semaglutide cost $249 a month, 25% above the $199 median for compounded semaglutide across the sellers we compare
- Tirzepatide cost $299 a month, 11% above the $269 median for compounded tirzepatide across the sellers we compare
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Luma Meds is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.
What Luma Meds charged
Luma Meds charged $140/month.
- Compounded semaglutide (monthly): $249/month
- Compounded semaglutide (3-month bundle): $140/month
- Compounded tirzepatide (monthly): $299/month
- Compounded tirzepatide (3-month bundle): $166/month
For compounded tirzepatide, the median across the sellers we compare is $269/month, so Luma Meds' $299 lands mid-market. Price is unlikely to be the deciding factor.
Live Vital dispenses semaglutide and tirzepatide from $130/month, which makes it the fair comparison to run before you commit here.
What Luma Meds dispensed
Luma Meds prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two molecules with the largest published weight-loss trial programs behind them. These are compounded preparations from a licensed pharmacy rather than approved pens, which is where the lower price comes from. A compounded drug is not FDA-approved as a finished product: the specific preparation has not been reviewed for safety, efficacy or manufacturing quality.
Safety and disclosure
Luma Meds told buyers its price before the medical questionnaire. It also offered clinician messaging between visits. We found no FDA warning letters issued to Luma Meds. How we weigh oversight, disclosure and price is set out in our scoring methodology.
Our read
Luma Meds is no longer taking new patients, so the choice is among the sellers that are still open. Ivim Health is the nearest comparison we review, and worth reading alongside this.
The Bottom Line
Luma Meds is closed and is not taking new patients. Its lowest price, $140 a month, was paid up front.
Where Luma Meds is the wrong choice
No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.
- If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
- If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
- If you want a human checking in, not just a prescription, consider Found.
If none of these fits, our guide to alternatives to Luma Meds sets more sellers in the same category beside Luma Meds on price, states and what the price includes.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this Luma Meds review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.